ARTICLE | Clinical News
subcutaneous Binocrit epoetin alfa regulatory update
April 25, 2016 7:00 AM UTC
The European Commission approved subcutaneous Binocrit epoetin alfa from Novartis’ Sandoz division to treat anemia in patients with chronic renal failure (CRF). Sandoz already markets an IV formulatio...